Nancy L. Lewis, MD, Clinical Director, Experimental Therapeutics, Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib (Stivarga).

The CORRECT trial enrolled 760 patients with heavily pretreated metastatic colorectal cancer (mCRC) who had exhausted all approved treatment options, including chemotherapy, bevacizumab (Avastin), cetuximab (Erbitux), and panitumumab (Vectibix). Patients were randomized 2:1 to receive regorafenib or placebo plus best supportive care for 21 days with 1 week off.

At the 2012 ESMO congress, the final analysis from the CORRECT trial for overall survival (OS) was presented and further confirmed the benefits of regorafenib. At the final analysis, median OS was 6.4 months for regorafenib compared to 5 months for placebo.

The FDA approved regorafenib on September 27, 2012, as a salvage therapy for patients with mCRC. Lewis believes the approval of regorafenib will play a major roll in allowing patients with mCRC to live longer.

Videos

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Nancy L. Lewis, MD

Articles

Dr. Nancy Lewis Discusses the Regorafenib CORRECT Trial